Microsoft Word ith2017ch7 final ePub accept all changes docx
Download 485.93 Kb. View original pdf
|
maleria !, maleria !, maleria !, maleria !, maleria !
- Navigate this page:
- P. falciparum
| 7.3 Treatment Patients who are non-immune are at high risk of malaria and its consequences. Early diagnosis and appropriate treatment can be lifesaving. For travellers who are treated for malaria in countries or areas of no risk, the following principles apply • All patients with suspected clinical malaria should be tested for malaria in a reliable diagnostic centre with microscopy or rapid diagnostic test. If no parasites are found in the first blood film, a series of blood samples should betaken at intervals of 6–12 hours and examined very carefully. When laboratory diagnostic results are delayed, treatment should be started on the based on clinical indicators and travel history. • If the patient has taken malaria chemoprophylaxis, the same medicine should not be used for treatment. • The possibility of mixed P. falciparum–P. vivax infections must always be considered. Travellers who acquire malaria while still in the malaria-endemic country should be treated in accordance with the national policy of the country. P. falciparum Chemoprophylaxis and treatment of falciparum malaria are becoming more complex because P. falciparum is increasingly resistant to various antimalarial drugs. Chloroquine can no longer be used for prevention and treatment of falciparum malaria. The following combination therapies are suitable for treatment of uncomplicated falciparum malaria in travellers on return to countries or areas of no risk • artemether–lumefantrine • dihydroartemisinin–piperaquine • atovaquone-proguanil. Note The artemisinin combination therapies are preferred because treatment failures are consistently lower than 5% in settings without resistance to the partner drug. Download 485.93 Kb. Share with your friends:
|